A designer sugar, KarboLyn®, leads to tighter sugar control than glucose in a pre-diabetic cohort

KarboLyn®, leads to glucose control in a pre-diabetic cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58611690

Enrollment

Registered

2016-11-22

Start date

2014-07-01

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Nutritional, Metabolic, Endocrine Diabetes

Interventions

Part 1: After an 8-hour fast (minumum), normal and pre-diabetic volunteers are randomized to one of two groups. Group 1: Participants receive 50g KarboLyn®

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Part 1: Healthy volunteers: 1. Aged 21 years and over 2. Healthy (not a pre-diabetic or diabetic) 3. Normal blood sugar level (fasting glucose is less than or equal to 100 mg/dl) Pre-diabetics: 1. Aged 21 years and over 2. Pre-diabetic not currently taking any diabetic related medication to control blood sugar level 3. Fasting blood sugar is greater than 100 mg/dl and less than 130 mg/dl Part 2: 1. Aged 21 years and over 2. Diabetic (fasting blood sugar is between 125 mg/dl and 200 mg/dl)

Exclusion criteria

Exclusion criteria: Parts 1 and 2: 1. Pregnancy 2. Heath condition making participant unable to walk on a treadmill for 2 hours

Design outcomes

Primary

Measure	Time frame
Blood sugar is measured by blood draws and standard glucose testing at ‘0’ (before consumption), and at 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, and 120 minutes for all volunteers.	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United States of America

Contacts

Public ContactJeff Golini

jeffg@allamericanpharmaceutical.com+1 406 245 5793

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026